ICON is a global clinical research organisation that has been helping pharmaceutical, biotechnology, medical device, and government clients bring drugs and devices to market since 1990. Starting with five people in Dublin, the company has grown to nearly 40,000 employees across 95 locations in 55 countries. In 2024 alone, ICON supported 1,465 clinical studies involving nearly 48,000 patients, worked with 406 customers, and contributed to 18 drug approvals.
The company provides outsourced development and commercialisation services throughout the drug and device lifecycle. Its work spans a broad range of therapeutic areas and combines domain expertise with technology solutions - including artificial intelligence and data analytics - to accelerate timelines, reduce costs, and improve quality. ICON positions itself as a trusted partner guiding clients through the complex process of clinical development.
ICON's growth has been both organic and through strategic acquisitions, reflecting its expansion across geographies and service capabilities. The organisation operates as a mission-driven enterprise focused on helping life-saving therapies reach patients faster, while managing the operational complexity that such work entails.
